Literature DB >> 31832578

Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.

Natalie I Vokes1,2, David Liu1,2, Biagio Ricciuti1, Elizabeth Jimenez-Aguilar3, Hira Rizvi4, Felix Dietlein1,2, Meng Xiao He5, Claire A Margolis1,2, Haitham A Elmarakeby1,2, Jeffrey Girshman4, Anika Adeni1, Francisco Sanchez-Vega4, Nikolaus Schultz4, Suzanne Dahlberg1, Ahmet Zehir4, Pasi A Jänne1,6,7, Mizuki Nishino1,6, Renato Umeton1,8, Lynette M Sholl6, Eliezer M Van Allen1,2, Matthew D Hellmann4,9, Mark M Awad1.   

Abstract

PURPOSE: Heterogeneity in tumor mutational burden (TMB) quantification across sequencing platforms limits the application and further study of this potential biomarker of response to immune checkpoint inhibitors (ICI). We hypothesized that harmonization of TMB across platforms would enable integration of distinct clinical datasets to better characterize the association between TMB and ICI response.
METHODS: Cohorts of NSCLC patients sequenced by one of three targeted panels or by whole exome sequencing (WES) were compared (total n=7297). TMB was calculated uniformly and compared across cohorts. TMB distributions were harmonized by applying a normal transformation followed by standardization to z-scores. In sub-cohorts of patients treated with ICIs (DFCI n=272; MSKCC n=227), the association between TMB and outcome was assessed. Durable clinical benefit (DCB) was defined as responsive/stable disease lasting ≥6 months.
RESULTS: TMB values were higher in the panel cohorts than the WES cohort. Average mutation rates per gene were highly concordant across cohorts (Pearson coefficient 0.842-0.866). Subsetting the WES cohort by gene panels only partially reproduced the observed differences in TMB. Standardization of TMB into z-scores harmonized TMB distributions and enabled integration of the ICI-treated sub-cohorts. Simulations indicated that cohorts >900 are necessary for this approach. TMB did not associate with response in never smokers or patients harboring targetable driver alterations, although these analyses were under-powered. Increasing TMB thresholds increased DCB rate, but DCB rates within deciles varied. Receiver operator curves yielded an area under the curve of 0.614 with no natural inflection point.
CONCLUSION: Z-score conversion harmonizes TMB values and enables integration of datasets derived from different sequencing panels. Clinical and biologic features may provide context to the clinical application of TMB, and warrant further study.

Entities:  

Year:  2019        PMID: 31832578      PMCID: PMC6907021          DOI: 10.1200/PO.19.00171

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


  40 in total

Review 1.  Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.

Authors:  Lizza E Hendriks; Etienne Rouleau; Benjamin Besse
Journal:  Transl Lung Cancer Res       Date:  2018-12

2.  First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Authors:  David P Carbone; Martin Reck; Luis Paz-Ares; Benjamin Creelan; Leora Horn; Martin Steins; Enriqueta Felip; Michel M van den Heuvel; Tudor-Eliade Ciuleanu; Firas Badin; Neal Ready; T Jeroen N Hiltermann; Suresh Nair; Rosalyn Juergens; Solange Peters; Elisa Minenza; John M Wrangle; Delvys Rodriguez-Abreu; Hossein Borghaei; George R Blumenschein; Liza C Villaruz; Libor Havel; Jana Krejci; Jesus Corral Jaime; Han Chang; William J Geese; Prabhu Bhagavatheeswaran; Allen C Chen; Mark A Socinski
Journal:  N Engl J Med       Date:  2017-06-22       Impact factor: 91.245

3.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

4.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Authors:  Robert M Samstein; Chung-Han Lee; Alexander N Shoushtari; Matthew D Hellmann; Ronglai Shen; Yelena Y Janjigian; David A Barron; Ahmet Zehir; Emmet J Jordan; Antonio Omuro; Thomas J Kaley; Sviatoslav M Kendall; Robert J Motzer; A Ari Hakimi; Martin H Voss; Paul Russo; Jonathan Rosenberg; Gopa Iyer; Bernard H Bochner; Dean F Bajorin; Hikmat A Al-Ahmadie; Jamie E Chaft; Charles M Rudin; Gregory J Riely; Shrujal Baxi; Alan L Ho; Richard J Wong; David G Pfister; Jedd D Wolchok; Christopher A Barker; Philip H Gutin; Cameron W Brennan; Viviane Tabar; Ingo K Mellinghoff; Lisa M DeAngelis; Charlotte E Ariyan; Nancy Lee; William D Tap; Mrinal M Gounder; Sandra P D'Angelo; Leonard Saltz; Zsofia K Stadler; Howard I Scher; Jose Baselga; Pedram Razavi; Christopher A Klebanoff; Rona Yaeger; Neil H Segal; Geoffrey Y Ku; Ronald P DeMatteo; Marc Ladanyi; Naiyer A Rizvi; Michael F Berger; Nadeem Riaz; David B Solit; Timothy A Chan; Luc G T Morris
Journal:  Nat Genet       Date:  2019-01-14       Impact factor: 38.330

5.  Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.

Authors:  Douglas B Johnson; Garrett M Frampton; Matthew J Rioth; Erik Yusko; Yaomin Xu; Xingyi Guo; Riley C Ennis; David Fabrizio; Zachary R Chalmers; Joel Greenbowe; Siraj M Ali; Sohail Balasubramanian; James X Sun; Yuting He; Dennie T Frederick; Igor Puzanov; Justin M Balko; Justin M Cates; Jeffrey S Ross; Catherine Sanders; Harlan Robins; Yu Shyr; Vincent A Miller; Philip J Stephens; Ryan J Sullivan; Jeffrey A Sosman; Christine M Lovly
Journal:  Cancer Immunol Res       Date:  2016-09-26       Impact factor: 11.151

6.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

7.  Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:  Ahmet Zehir; Ryma Benayed; Ronak H Shah; Aijazuddin Syed; Sumit Middha; Hyunjae R Kim; Preethi Srinivasan; Jianjiong Gao; Debyani Chakravarty; Sean M Devlin; Matthew D Hellmann; David A Barron; Alison M Schram; Meera Hameed; Snjezana Dogan; Dara S Ross; Jaclyn F Hechtman; Deborah F DeLair; JinJuan Yao; Diana L Mandelker; Donavan T Cheng; Raghu Chandramohan; Abhinita S Mohanty; Ryan N Ptashkin; Gowtham Jayakumaran; Meera Prasad; Mustafa H Syed; Anoop Balakrishnan Rema; Zhen Y Liu; Khedoudja Nafa; Laetitia Borsu; Justyna Sadowska; Jacklyn Casanova; Ruben Bacares; Iwona J Kiecka; Anna Razumova; Julie B Son; Lisa Stewart; Tessara Baldi; Kerry A Mullaney; Hikmat Al-Ahmadie; Efsevia Vakiani; Adam A Abeshouse; Alexander V Penson; Philip Jonsson; Niedzica Camacho; Matthew T Chang; Helen H Won; Benjamin E Gross; Ritika Kundra; Zachary J Heins; Hsiao-Wei Chen; Sarah Phillips; Hongxin Zhang; Jiaojiao Wang; Angelica Ochoa; Jonathan Wills; Michael Eubank; Stacy B Thomas; Stuart M Gardos; Dalicia N Reales; Jesse Galle; Robert Durany; Roy Cambria; Wassim Abida; Andrea Cercek; Darren R Feldman; Mrinal M Gounder; A Ari Hakimi; James J Harding; Gopa Iyer; Yelena Y Janjigian; Emmet J Jordan; Ciara M Kelly; Maeve A Lowery; Luc G T Morris; Antonio M Omuro; Nitya Raj; Pedram Razavi; Alexander N Shoushtari; Neerav Shukla; Tara E Soumerai; Anna M Varghese; Rona Yaeger; Jonathan Coleman; Bernard Bochner; Gregory J Riely; Leonard B Saltz; Howard I Scher; Paul J Sabbatini; Mark E Robson; David S Klimstra; Barry S Taylor; Jose Baselga; Nikolaus Schultz; David M Hyman; Maria E Arcila; David B Solit; Marc Ladanyi; Michael F Berger
Journal:  Nat Med       Date:  2017-05-08       Impact factor: 53.440

8.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962

9.  The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.

Authors:  Andrea Garofalo; Lynette Sholl; Brendan Reardon; Amaro Taylor-Weiner; Ali Amin-Mansour; Diana Miao; David Liu; Nelly Oliver; Laura MacConaill; Matthew Ducar; Vanesa Rojas-Rudilla; Marios Giannakis; Arezou Ghazani; Stacy Gray; Pasi Janne; Judy Garber; Steve Joffe; Neal Lindeman; Nikhil Wagle; Levi A Garraway; Eliezer M Van Allen
Journal:  Genome Med       Date:  2016-07-26       Impact factor: 11.117

10.  Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.

Authors:  Diana M Merino; Lisa M McShane; David Fabrizio; Vincent Funari; Shu-Jen Chen; James R White; Paul Wenz; Jonathan Baden; J Carl Barrett; Ruchi Chaudhary; Li Chen; Wangjuh Sting Chen; Jen-Hao Cheng; Dinesh Cyanam; Jennifer S Dickey; Vikas Gupta; Matthew Hellmann; Elena Helman; Yali Li; Joerg Maas; Arnaud Papin; Rajesh Patidar; Katie J Quinn; Naiyer Rizvi; Hongseok Tae; Christine Ward; Mingchao Xie; Ahmet Zehir; Chen Zhao; Manfred Dietel; Albrecht Stenzinger; Mark Stewart; Jeff Allen
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751

View more
  28 in total

1.  High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.

Authors:  D J McGrail; P G Pilié; N U Rashid; L Voorwerk; M Slagter; M Kok; E Jonasch; M Khasraw; A B Heimberger; B Lim; N T Ueno; J K Litton; R Ferrarotto; J T Chang; S L Moulder; S-Y Lin
Journal:  Ann Oncol       Date:  2021-03-15       Impact factor: 32.976

Review 2.  [Immunotherapy for non-small cell lung cancer (NSCLC)].

Authors:  Nikolaj Frost; Martin Reck
Journal:  Inn Med (Heidelb)       Date:  2022-06-15

3.  Multiparametric immune profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: an exploratory study of the CLAP trial.

Authors:  Yin Wang; Yuerong Lai; Chongjie Tong; Xin Huang; Hongyu Peng; Shumei Yan; Zhimin Liu
Journal:  Clin Transl Oncol       Date:  2022-09-17       Impact factor: 3.340

4.  Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.

Authors:  Wenya Linda Bi; Lakshmi Nayak; David M Meredith; Joseph Driver; Ziming Du; Samantha Hoffman; Yvonne Li; Eudocia Quant Lee; Rameen Beroukhim; Mikael Rinne; Ricardo McFaline-Figueroa; Ugonma Chukwueke; Christine McCluskey; Sarah Gaffey; Andrew D Cherniack; Jennifer Stefanik; Lisa Doherty; Christina Taubert; Meghan Cifrino; Deborah LaFrankie; Thomas Graillon; Patrick Y Wen; Keith L Ligon; Ossama Al-Mefty; Raymond Y Huang; Alona Muzikansky; E Antonio Chiocca; Sandro Santagata; Ian F Dunn; David A Reardon
Journal:  Neuro Oncol       Date:  2022-01-05       Impact factor: 12.300

5.  Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.

Authors:  Xin Huang; Minjun He; Hongyu Peng; Chongjie Tong; Zhimin Liu; Fan Yang; Chunyan Lan; Xiaolong Zhang; Yang Shao; Dongqin Zhu; Junli Zhang; Jiani C Yin
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

6.  Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer.

Authors:  Xinan Wang; Biagio Ricciuti; Tom Nguyen; Xihao Li; Michael S Rabin; Mark M Awad; Xihong Lin; Bruce E Johnson; David C Christiani
Journal:  Cancer Res       Date:  2021-03-02       Impact factor: 13.312

Review 7.  The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.

Authors:  Denis L Jardim; Aaron Goodman; Debora de Melo Gagliato; Razelle Kurzrock
Journal:  Cancer Cell       Date:  2020-10-29       Impact factor: 31.743

8.  Enhanced Antitumor Response to Immune Checkpoint Blockade Exerted by Cisplatin-Induced Mutagenesis in a Murine Melanoma Model.

Authors:  Falih M Gorgun; Steven G Widen; Douglas S Tyler; Ella W Englander
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

9.  Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.

Authors:  Xinan Wang; Biagio Ricciuti; Joao V Alessi; Tom Nguyen; Mark M Awad; Xihong Lin; Bruce E Johnson; David C Christiani
Journal:  J Natl Cancer Inst       Date:  2021-06-11       Impact factor: 11.816

10.  Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.

Authors:  Alexander Drilon; Michael Duruisseaux; Ji-Youn Han; Masaoki Ito; Christina Falcon; Soo-Ryum Yang; Yonina R Murciano-Goroff; Haiquan Chen; Morihito Okada; Miguel Angel Molina; Marie Wislez; Philippe Brun; Clarisse Dupont; Eva Branden; Giulio Rossi; Alexa Schrock; Siraj Ali; Valérie Gounant; Fanny Magne; Torsten Gerriet Blum; Alison M Schram; Isabelle Monnet; Jin-Yuan Shih; Joshua Sabari; Maurice Pérol; Viola W Zhu; Misako Nagasaka; Robert Doebele; D Ross Camidge; Maria Arcila; Sai-Hong Ignatius Ou; Denis Moro-Sibilot; Rafael Rosell; Lucia Anna Muscarella; Stephen V Liu; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2021-06-02       Impact factor: 50.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.